New York, NY -- (SBWIRE) -- 12/17/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Strategic Hotels and Resorts Inc (NYSE:BEE), Monster Worldwide, Inc (NYSE:MWW), Dendreon Corporation (NASDAQ: DNDN)
Strategic Hotels and Resorts Inc (NYSE:BEE) the stock opened the session at $8.81but then moved to $9.15. At that price, the stock showed a positive performance of 3.98%. Strategic Hotels & Resorts, Inc. (SHR) operates as a self-administered and self-managed real estate investment trust (REIT). As of December 31, 2012, the Company’s portfolio included 18 full-service hotel interests located in urban and resort markets in the United States; Punta Mita, Nayarit, Mexico;
Will BEE Continue To Move Higher? Find Out Here
Monster Worldwide, Inc (NYSE:MWW) opened the session at $5.77 and closed the session at $5.93. The stock showed a positive performance of 3.49% in previous trading session. The beta of the stock remained 2.76. Monster Worldwide, Inc. (Monster Worldwide) is parent company of Monster, the global online employment solution. With a presence in approximately 55 countries globally, including key markets in North America, Europe, South America and the Asia-Pacific region, Monster offers online recruiting solutions. Through online media sites and services,
Why Should Investors Buy MWW After The Recent Gain? Just Go Here and Find Out
Dendreon Corporation (NASDAQ: DNDN) traded with volume of 2.89 million shares in the prior session and the average volume of the stock remained 3.49 million shares. The beta of the stock remained 5.04. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers.
Will DNDN Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)